Thyroid function test variability and cardiovascular morbidity in hyperthyroidism
Authors' conclusion
During ATD therapy, fT4 variability is associated with an increased cardiovascular morbidity. Although positive TRAbs are associated with a lower cardiovascular morbidity compared with hyperthyroidism with negative autoantibodies, the variability of fT4 is associated with cardiovascular morbidity also in patients with positive TRAbs.
Study context
- Population
- Hyperthyroid patients treated with antithyroid drug (ATD) therapy at Tampere University Hospital, March 2016–December 2018
- Participants
- 394 patients
- Outcome
- Cardiovascular disease (CVD)-associated hospital visits (cardiovascular morbidity) in relation to TFT variability (CVs of thyroid-stimulating hormone (TSH), FT4, FT3)
- Follow-up
- Median 1.5 years (IQR 0.8-2.0)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Age, OR
1.06
95% CI 1.03–1.09
Male gender, OR
2.33
95% CI 1.03–5.28
FT4-CV, OR
1.02
95% CI 1.01–1.04
Baseline positive thyrotropin receptor antibodies (TRAbs), lower cardiovascular morbidity, OR
0.29
95% CI 0.14–0.61
Observational data: associations, not effects.
Further findings
FT4-CV and cardiovascular morbidity in patients with baseline TRAb positivity
- FT4-CV, OR
- 1.03 (95% CI 1.00-1.05)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →